The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 April 2026•

1 min read

Harrow Stock Analysis: Market Overreaction Creates Strong Buy Opportunity

Key Facts

1Harrow is rated as a 'Strong Buy' with a fair value estimate of $73.25.

2Analysts project long-term growth driven by Vevye and Iheezo despite recent guidance disappointment.

Analysts at Seeking Alpha have reiterated a 'Strong Buy' rating for Harrow (HROW), setting a fair value target of $73.25, which implies an upside potential of over 100%. The analysis suggests that the recent sell-off in the stock is a market overreaction to short-term guidance disappointments. Long-term growth is expected to be driven by the company's core assets, Vevye and Iheezo, which remain fundamentally strong. The financial model projects a robust EBIT margin of 32–45% for the period between 2029 and 2035. These projections underscore analyst confidence in Harrow's long-term trajectory despite current market volatility. Consequently, the current valuation gap is viewed as a significant buying opportunity for investors looking for growth in the pharmaceutical sector.